TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas

IDH mutations frequently occur in WHO grade II and III diffuse gliomas and have favorable prognosis compared to wild-type tumors. However, whether IDH mutations in WHO grade II and II diffuse gliomas predict enhanced sensitivity to adjuvant radiation (RT) or chemotherapy (CHT) is still being debated...

Full description

Bibliographic Details
Main Authors: Zhang, Zhen-Yu, Chan, Aden Ka-Yin, Ding, Xiao-Jie, Qin, Zhi-Yong, Hong, Christopher S., Chen, Ling-Chao, Zhang, Xin, Zhao, Fang-Ping, Wang, Yin, Wang, Yang, Zhou, Liang-Fu, Zhuang, Zhengping, Ng, Ho-Keung, Yan, Hai, Yao, Yu, Mao, Ying
Format: Online
Language:English
Published: Impact Journals LLC 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694799/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694799/

Similar Items